Human epidermal growth factor receptor 2 (HER2) is amplified/overexpressed in approximately 15% of all breast cancer cases [3], making treatment recommendations for MBC highly dependent on hormone receptor (HR) and HER2 status [3, 4]. This evidence concerns the gene ERBB2 and breast cancer.